Lobbying Filing Details

Total Spending

$850,000

Activities

5

Lobbyists

11

Gov't Entities

60

Filing Information
Filing UUID:
295068e1-d0a0-4b03-89f8-6cde7237ce40
Type:
Q2 - 2nd Quarter - Report
Period:
2020 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
July 21, 2020 at 12:24 AM
Income:
$0
Expenses:
$850,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Beth Anne Cole
Registrant
ASSOCIATION FOR ACCESSIBLE MEDICINES

Association representing the interests of the generic pharmaceutical industry.

Washington, District of Columbia
Client
ASSOCIATION FOR ACCESSIBLE MEDICINES
District of Columbia, United States of America
Lobbying Activities (5)
Activity 1
Budget/Appropriations

FDA Funding.
H.R.1865: Further Consolidated Appropriations Act, 2020.
S.4049: National Defense Authorization Act for Fiscal Year 2021.
Public Law 115-141: Consolidated Appropriations Act of 2018.

Lobbyists (7)
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • KATHERINE RAAB
Government Entities (12)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • White House Office
  • Office of the Vice President of the United States
  • U.S. Trade Representative (USTR)
  • ... and 7 more
Activity 2
Copyright/Patent/Trademark

Patent Settlements.
Patent Abuse.
Accelerating the Patent Dance.
BPCIA Patent Dance.
Inter Partes Review.
Section 1498.
H.R.3666: STRONGER Patents Act of 2019.

Lobbyists (5)
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
Government Entities (12)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • White House Office
  • Office of the Vice President of the United States
  • U.S. Trade Representative (USTR)
  • ... and 7 more
Activity 3
Medicare/Medicaid

Medicare Part D Program and Generic Drugs.
Medicare Reimbursement for Biosimilars.
Medicaid Rebate Penalty.
Medicare Part D Low Income Subsidy (LIS) Program.
Medicare Part D Coverage Gap Discount Program.
H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
Medicare Shared Savings Program.
H.R.6179: Increasing Access to Biosimilars Act of 2020.
S.1895: Lower Health Care Costs Act.

Lobbyists (8)
  • CHRISTINE SIMMON
  • CHRISTOPHER BOWLIN
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JOSEPH STEWART
  • KATHERINE RAAB
Government Entities (12)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • White House Office
  • Office of the Vice President of the United States
  • U.S. Trade Representative (USTR)
  • ... and 7 more
Activity 4
Pharmacy

Implementation of Food and Drug Administration Reauthorization Act (FDARA).
FDA Inspections.
FDA Enforcement Discretion.
Consent to FDA Approval.
Generic Drug User Fee Amendments (GDUFA).
Biosimilar User Fee Act (BsUFA).
Labeling of Generic Drugs and Biosimilars.
Country of Manufacture Labeling.
S.3537: A bill to require the Secretary of Health and Human Services to maintain a list of the country of origin of all drugs marketed in the United States, to ban the use of Federal funds for the purchase of drugs manufactured in China, and for other purposes.
S.3538: A bill to require the Secretary of Defense to submit to Congress a report on the reliance by the Department of Defense on imports of certain pharmaceutical products made in part or in whole in certain countries, to establish postmarket reporting requirements for pharmaceuticals, and for other purposes.
Continuous Manufacturing.
Approval of Supplements to ANDA Changing Manufacturing Locations.
Drug Shortages.
S.2723: Mitigating Emergency Drug Shortages Act.
H.R.4398: Affordable Prescriptions for Patients Through Promoting Competition Act of 2019.
Biosimilars Naming.
Biosimilars Insulin.
Pass Through Payments for Biosimilars.
Cost Sharing for Biosimilars.
H.R.4455: BIOSIM Act.
H.R.4597: Acting to Cancel Copays and Ensure Substantial Savings for Biosimilars Act of 2019.
H.R.4629: Star Rating for Biosimilars Act.
Prescription Drug Costs.
Drug Pricing.
American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
H.R.4913: To amend title XVIII of the Social Security Act to require PDP sponsors of a prescription drug plan under part D of the Medicare program that use a formulary to include certain generic drugs and biosimilar biological products on such formulary, and for other purposes.
180-Day Exclusivity.
S.2543: Prescription Drug Pricing Reduction Act (PDPRA) of 2019.
H.R.938: Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019.
H.R.465/S.102: Prescription Drug Price Relief Act of 2019.
H.R.3: Lower Drug Costs Now Act of 2019.
S.1895: Lower Health Care Costs Act.
Reciprocal Marketing Authorization.
Risk Evaluation and Mitigation Strategies (REMS).
Pharmaceutical Exclusivity.
30-Month Stays.
S.659: Biologic Patent Transparency Act.
Biologics Price Competition and Innovation Act (BPCIA).
Purple Book Modernization.
Orange Book.
Issues Related to COVID-19.
Implementation of H.R.748/S.3548: Coronavirus Aid, Relief, and Economic Security (CARES) Act.
Implementation of H.R.6201: Families First Coronavirus Response Act.
Implementation of S.3630: Facilitating Innovation to Fight Coronavirus Act.
Rubio Coronavirus Plan.
Commission on Americas Medical Security Act.
Buy American Proposals.
Buy American Executive Order.
S.3478: A bill to require a report to assess, evaluate, and address the dependence of the United States on critical drugs and devices sourced or manufactured outside of the United States.

Lobbyists (11)
  • CHRISTINE SIMMON
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • DAVID R. GAUGH
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JONATHAN KIMBALL
  • JOSEPH STEWART
  • KATHERINE RAAB
Government Entities (12)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • White House Office
  • Office of the Vice President of the United States
  • U.S. Trade Representative (USTR)
  • ... and 7 more
Activity 5
Trade (domestic/foreign)

General Trade Issues.
Pharmaceutical Exclusivity.
Quality Supply Chain.
Drug Supply Chain.
AAM Blueprint to Enhance the Security of the U.S. Supply Chain.
H.R.6049/S.3343: Medical Supply Chain Security Act.
H.R.6393/S.3538: Strengthening Americas Supply Chain and National Security Act.
S. ___More Accurate Supply Chain Information.
Air Transport of Pharmaceuticals.
United States-Mexico-Canada Agreement (USMCA).
U.S.-UK Trade Agreement.
U.S.-Kenya Trade Discussions.
U.S.-India Trade Discussions.
U.S.-European Trade Discussions.
U.S.-China Trade Discussions.
Secretary Azar Importation Plan.

Lobbyists (11)
  • CHRISTINE SIMMON
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • DAVID R. GAUGH
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • KARIN HESSLER
  • JONATHAN KIMBALL
  • JOSEPH STEWART
  • KATHERINE RAAB
Government Entities (12)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • White House Office
  • Office of the Vice President of the United States
  • U.S. Trade Representative (USTR)
  • ... and 7 more

Source: LDA.gov, data retrieved November 4, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.